Cargando…

Effects of a Long-Acting Formulation of Octreotide on Patients with Portal Hypertension

OBJECTIVE: This study aimed to determine whether the treatment of a long-acting formulation of octreotide (OCT-LAR) exerted a similar effect on improving the prognosis of patients with portal hypertension compared with placement of transjugular intrahepatic portosystemic shunts (TIPSs). METHODS: A t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cui, Pei-Jing, Yao, Jing, Zhu, Yin, Zhang, Zheng-Yun, Yang, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2017
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569631/ https://www.ncbi.nlm.nih.gov/pubmed/28855918 http://dx.doi.org/10.1155/2017/3943210

Ejemplares similares

Preparation of long-acting microspheres loaded with octreotide for the treatment of portal hypertensive
por: Han, Bing, et al.
Publicado: (2021)

Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide
por: Cebon, J
Publicado: (2006)

Pharmacokinetic and technical comparison of Sandostatin(® )LAR(® )and other formulations of long-acting octreotide
por: Petersen, Holger, et al.
Publicado: (2011)

Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study
por: Verset, G, et al.
Publicado: (2007)

Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats
por: Gao, Jin-Hang, et al.
Publicado: (2016)

Correction: Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats
por: Gao, Jin-Hang, et al.
Publicado: (2022)

Transjugular Intrahepatic Portosystemic Shunt for the Treatment of Portal Hypertension in Noncirrhotic Patients with Portal Cavernoma
por: Luo, Xuefeng, et al.
Publicado: (2014)

Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study
por: Li, Jie, et al.
Publicado: (2016)

The somatostatin analogue octreotide inhibits angiogenesis in the earliest, but not in advanced, stages of portal hypertension in rats
por: Mejias, Marc, et al.
Publicado: (2008)

Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers
por: Tiberg, Fredrik, et al.
Publicado: (2015)

Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial
por: Chrispijn, Melissa, et al.
Publicado: (2011)

Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours
por: Laskaratos, Faidon-Marios, et al.
Publicado: (2016)

Correlation between Endosonographic and Doppler Ultrasound Features of Portal Hypertension in Patients with Cirrhosis
por: Wiechowska-Kozłowska, A., et al.
Publicado: (2012)

Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives
por: Yau, Hanford, et al.
Publicado: (2017)

Efficacy and adverse events of octreotide long-acting release in acromegaly: a real-world retrospective study
por: Zhao, Zhe, et al.
Publicado: (2022)

An obscure cause of gastrointestinal bleeding: Recurrent duodenal variceal hemorrhage treated with intramuscular octreotide in the absence of portal hypertension
por: O'Neill, Robert S, et al.
Publicado: (2022)

A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
por: Mercado, Moises, et al.
Publicado: (2007)

Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study
por: Neggers, Sebastian JCMM, et al.
Publicado: (2015)

Liver and Spleen Stiffness Measurements for Assessment of Portal Hypertension Severity in Patients with Budd Chiari Syndrome
por: Dajti, Elton, et al.
Publicado: (2019)

Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
por: Koumarianou, Anna, et al.
Publicado: (2012)

Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors
por: Cheng, Yue, et al.
Publicado: (2023)

Sinistral portal hypertension
por: Thompson, Richard J, et al.
Publicado: (2006)

Spontaneous porto‐femoral shunting in long‐standing portal hypertension
por: Giuffrè, Mauro, et al.
Publicado: (2020)

Assessment of Haemodynamic Response to Nonselective Beta-Blockers in Portal Hypertension by Phase-Contrast Magnetic Resonance Angiography
por: McDonald, Natasha, et al.
Publicado: (2017)

Prior Esophagogastric Devascularization Followed by Splenectomy for Liver Cirrhosis with Portal Hypertension: A Modified Laparoscopic Technique
por: Zhang, Lei, et al.
Publicado: (2019)

Overexpression of P-glycoprotein, MRP2, and CYP3A4 impairs intestinal absorption of octreotide in rats with portal hypertension
por: Sun, Xiaoyu, et al.
Publicado: (2021)

Computed tomography combined with gastroscopy for assessment of pancreatic segmental portal hypertension
por: Wang, Yu-Li, et al.
Publicado: (2022)

Catecholamine-secreting carotid body paraganglioma: successful preoperative control of hypertension and clinical symptoms using high-dose long-acting octreotide
por: Elshafie, Omayma, et al.
Publicado: (2014)

Gender differences in vascular reactivity of mesenteric arterioles in portal hypertensive and non-portal hypertensive rats
por: Zhang, Bin, et al.
Publicado: (2019)

Doppler waveform study as indicator of change of portal pressure after administration of octreotide
por: Haider, Shahbaz, et al.
Publicado: (2016)

Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study
por: Shen, Ming, et al.
Publicado: (2018)

Wall shear stress in portal vein of cirrhotic patients with portal hypertension
por: Wei, Wei, et al.
Publicado: (2017)

Successful use of long acting octreotide in two cases with Beckwith-Wiedemann syndrome and severe hypoglycemia
por: Al-Zubeidi, Hiba, et al.
Publicado: (2014)

Pathological abnormalities in splenic vasculature in non-cirrhotic portal hypertension: Its relevance in the management of portal hypertension
por: Gupta, Shahana, et al.
Publicado: (2020)

Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis
por: Strosberg, Jonathan R, et al.
Publicado: (2015)

Efficacy of long-acting release octreotide for preventing chemotherapy-induced diarrhoea: protocol for a systematic review
por: Deng, Chao, et al.
Publicado: (2017)

Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors
por: Saif, Muhammad Wasif, et al.
Publicado: (2018)

In situ subtotal spleen resection combined with selective pericardial devascularization for the treatment of portal hypertension
por: Li, Hai-Lin, et al.
Publicado: (2023)

Computed tomography perfusion in differentiating portal hypertension: A correlation study with hepatic venous pressure gradient
por: Dong, Jian, et al.
Publicado: (2023)

Inhibition of P-glycoprotein, multidrug resistance-associated protein 2 and cytochrome P450 3A4 improves the oral absorption of octreotide in rats with portal hypertension
por: Sun, Xiao-Yu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5h88ms3i8cno4t2qjcr7l1jitp